BlepharitisPhase 2VISTA-1XNCT07904767
A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis
A Phase 2 study testing APT-001 topical ophthalmic ointment (spinosad) in people with Blepharitis, run by Aperta Biosciences, LLC at 2 sites in Guatemala.
Trial summary
The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to placebo, and to establish that the therapeutic is safe and generally well tolerated by patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Blepharitis
- What is being tested?
- APT-001 topical ophthalmic ointment (spinosad)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15 participants
- Where
- 2 sitesGuatemala
- Study dates
- Dec 2026to Feb 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Symptomatic blepharitis
- At least 18 years of age
- Eyelid collarette score of at least 2
- Demodex mite density of at least 1.5 mites per lash or higher
- Willing and able to follow all instructions and attend all study visit
- Able to avoid prohibited medication for the duration of the study
- Patients can willingly provide consent on the informed consent form
Who cannot join
- Women with confirmed pregnancies
- Utilizing any medical or surgical therapy for acute or subacute conditions of the eye
- History of allergic reaction to spinosad or any formulation component
- Patients using eyelid hygiene or other treatment(s) for blepharitis within 14 days of screening
- History of ocular surgery within the past 3 months
- Presence of other ocular diseases that may affect study outcomes
Show all 9Show fewer
- Use of investigational drug, chronic glaucoma medications, or steroids
- Uncontrolled systemic disease
- Acute or chronic illness that would confound study results
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Guatemala2 sites
EyeScan, Imágenes Diagnósticas Oculares, S. A.
Guatemala City
Glendy Martinez, +502 5930-5051, Eyescangt@gmail.com
Rudy Oliver Gutierrez Paz, MD
Hospital de Día, Clínica de Ojos Doctor Gutiérrez
Guatemala City
Ozen Martinez, +502-2236-4100, servicioalcliente@clinicasdrgutierrez.com
Rudy Gutierrez Diaz, MD
About this study
Official title: Vision and Inflammation Study Testing Anti-acarid Therapeutics (VISTA-1X): A Phase 2, Open-Label, Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Adults With Blepharitis.
The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to placebo, and to establish that the therapeutic is safe and generally well tolerated by patients.
Read the detailed description
This Phase 2 study is an open-label trial to compare the safety and efficacy of APT-001 1.8% to placebo control for the treatment of blepharitis. The primary objective of the study is to compare the safety and efficacy of APT-001 compared to placebo from Day 1 to Day 15 in patients with blepharitis. The primary efficacy endpoint will be cure based upon collarettes. Safety will be determined by assessing adverse effects related to the treatment.
- Conditions
- Blepharitis
- Being tested
- APT-001 topical ophthalmic ointment (spinosad), Placebo control for APT-001 topical ophthalmic ointment
- Keywords
- Blepharitis
- Medical subject headings
- Blepharitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
APT-001 topical ophthalmic ointment (spinosad)Drug
APT-001 topical ophthalmic ointment (spinosad), administered once
Placebo control for APT-001 topical ophthalmic ointmentDrug
Placebo control for APT-001 topical ophthalmic ointment, administered once
| Study group | Role | What they receive |
|---|---|---|
| Active | Active comparator | APT-001 topical ophthalmic ointment, administered once Receives: Drug: APT-001 topical ophthalmic ointment (spinosad) |
| Placebo control for APT-001 topical ophthalmic ointment, administered once | Placebo comparator | Not described Receives: Drug: Placebo control for APT-001 topical ophthalmic ointment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Demodex mite killing
Number of living Demodex mites following treatment
Measured: From enrollment to last visit at 2 weeks
Secondary outcomes (3)
Rate of Collarette Cure
Eyelid collarette score 0
Measured: From enrollment to last visit at 2 weeks
Rate of Erythema Cure
Erythema Cure Rate
Measured: From enrollment to last visit at 2 weeks
Average Demodex mite density
Demodex mite density
Measured: From enrollment to last visit at 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2026
- Study startDec 2026 (estimated)
- Primary completionJan 2027 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BlepharitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aperta Biosciences, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Josue Moran, Ph.D., Study director, Aperta Biosciences, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07904767
- Sponsor's protocol ID
- VISTA-1X
- Acronym
- VISTA-1X
- Status last verified
- Oct 2026
- First submitted
- 23 Oct 2026
- Last updated
- 30 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vision and Inflammation Study Testing Anti-acarid Therapeutics (VISTA-1X): A Phase 2, Open-Label, Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Adults With Blepharitis.
- ClinicalTrials.gov ID
- NCT07904767
- Acronym / sponsor ID
- VISTA-1X / VISTA-1X
- Conditions
- Blepharitis
- Keywords
- Blepharitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Aperta Biosciences, LLCIndustry (pharma, biotech, devices)
- Study start
- Dec 2026 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 29 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to placebo, and to establish that the therapeutic is safe and generally well tolerated by patients.
Detailed description
This Phase 2 study is an open-label trial to compare the safety and efficacy of APT-001 1.8% to placebo control for the treatment of blepharitis. The primary objective of the study is to compare the safety and efficacy of APT-001 compared to placebo from Day 1 to Day 15 in patients with blepharitis. The primary efficacy endpoint will be cure based upon collarettes. Safety will be determined by assessing adverse effects related to the treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active | Active comparator | Drug: APT-001 topical ophthalmic ointment (spinosad)APT-001 topical ophthalmic ointment, administered once |
| Placebo control for APT-001 topical ophthalmic ointment, administered once | Placebo comparator | Drug: Placebo control for APT-001 topical ophthalmic ointment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Symptomatic blepharitis
- At least 18 years of age
- Eyelid collarette score of at least 2
- Demodex mite density of at least 1.5 mites per lash or higher
- Willing and able to follow all instructions and attend all study visit
Key exclusion criteria (9 listed)
- Women with confirmed pregnancies
- Utilizing any medical or surgical therapy for acute or subacute conditions of the eye
- History of allergic reaction to spinosad or any formulation component
- Patients using eyelid hygiene or other treatment(s) for blepharitis within 14 days of screening
- History of ocular surgery within the past 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| APT-001 topical ophthalmic ointment (spinosad)APT-001 topical ophthalmic ointment (spinosad), administered once | Drug | Active |
| Placebo control for APT-001 topical ophthalmic ointmentPlacebo control for APT-001 topical ophthalmic ointment, administered once | Drug | Placebo control for APT-001 topical ophthalmic ointment, administered once |
Primary outcome
Demodex mite killing
Time frame: From enrollment to last visit at 2 weeks
Number of living Demodex mites following treatment
3 secondary outcomes
Rate of Collarette Cure
Time frame: From enrollment to last visit at 2 weeks
Rate of Erythema Cure
Time frame: From enrollment to last visit at 2 weeks
Average Demodex mite density
Time frame: From enrollment to last visit at 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Blepharitis
RecruitingObservational study
Ocular Dysbiosis in Eyelid Disease
Anterior Blepharitis
Not yet recruitingPhase 4
Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study
Anterior Blepharitis
RecruitingObservational study
Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye
Artifical Intelligence, Cataract
RecruitingPhase 2
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Demodex Blepharitis
Recruiting
Photobiomodulation With REd vs BluE Light (REBEL)
Dry Eye Syndromes, Meibomian Gland Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Josue Moran, Ph.D. study director
Aperta Biosciences, LLC
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing APT-001 topical ophthalmic ointment (spinosad) in people with Blepharitis, run by Aperta Biosciences, LLC at 2 sites in Guatemala.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Guatemala. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Josue Moran, Ph. D. (512-270-3960, vista@apertabio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Demodex mite killing (time frame: From enrollment to last visit at 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.